Novel immunotherapies for hematologic malignancies
- 15 December 2014
- journal article
- review article
- Published by Wiley in Immunological Reviews
- Vol. 263 (1) , 90-105
Abstract
Summary: The immune system is designed to discriminate between self and tumor tissue. Through genetic recombination, there is fundamentally no limit to the number of tumor antigens that immune cells can recognize. Yet, tumors use a variety of immunosuppressive mechanisms to evade immunity. Insight into how the immune system interacts with tumors is expanding rapidly and has accelerated the translation of immunotherapies into medical breakthroughs. Herein, we appraise novel strategies that exploit the patient's immune system to kill cancer. We review various forms of immune‐based therapies, which have shown significant promise in patients with hematologic malignancies, including (i) conventional monoclonal therapies like rituximab; (ii) engineered monoclonal antibodies called bispecific T‐cell engagers; (iii) monoclonal antibodies and pharmaceutical drugs that block inhibitory T‐cell pathways (i.e. PD‐1, CTLA‐4, and IDO); and (iv) adoptive cell transfer therapy with T cells engineered to express chimeric antigen receptors or T‐cell receptors. We also assess the idea of using these therapies in combination and conclude by suggesting multi‐prong approaches to improve treatment outcomes and curative responses in patients.Keywords
Funding Information
- National Institutes of Health (1R01CA175061-02)
- American Cancer Society (122704-PF-13-084-01-LIB)
This publication has 183 references indexed in Scilit:
- Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancerBritish Journal of Cancer, 2013
- Ex Vivo Interleukin-12-Priming During CD8+ T Cell Activation Dramatically Improves Adoptive T Cell Transfer Antitumor Efficacy in a Lymphodepleted HostJournal of the American College of Surgeons, 2012
- Antibody-Based Immunotherapy of CancerCell, 2012
- Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular SignatureImmunity, 2011
- A human memory T cell subset with stem cell–like propertiesNature Medicine, 2011
- CARs on Track in the ClinicMolecular Therapy, 2011
- Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+The Prostate, 2009
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cellsNature Medicine, 2009
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunityNature Reviews Immunology, 2004